Hyperliquid Strategies Inc. (Nasdaq: PURR) - Deep Dive Research Report

Prepared 2026-06-17. Financial Services / Digital Asset Treasury. Fiscal year ends June 30.

Reporting-period note. Today is 2026-06-17. PURR reports on a June 30 fiscal year. The most recent completed quarter is Q3 FY2026 (ended March 31, 2026), reported via 10-Q and discussed on the earnings webcast of May 7, 2026 - within 90 days of today, so it anchors this report. A critical structural fact governs the whole document: the company has only existed as a digital-asset treasury since the reverse merger closed on December 2, 2025. There are therefore only two earnings calls in its life as Hyperliquid Strategies (Q2 FY2026 ended Dec 31, 2025, call ~Feb 11, 2026; and Q3 FY2026, call May 7, 2026). The "six most recent concalls" cannot exist for this entity - the prior calls under the CIK belong to Sonnet BioTherapeutics, a clinical-stage cancer-biotech with no relationship to the current business. I use the two real calls and flag this explicitly in Section 9 rather than fabricate continuity.

Section 1: What the company does

Hyperliquid Strategies Inc. is a holding company whose entire purpose is to own one crypto token - HYPE, the native token of the Hyperliquid blockchain - on behalf of public-market shareholders, and to make each share represent as much HYPE as possible over time. It is a "digital asset treasury" (DAT): the same structural idea Michael Saylor's Strategy (formerly MicroStrategy) pioneered with Bitcoin, but applied to HYPE. You buy the stock (PURR), the company holds the token, and the stock is supposed to track - and ideally grow faster than - the per-share quantity of that token.

The reason the wrapper exists at all is access. HYPE is hard for U.S. investors and institutions to buy directly: it does not trade on the major regulated U.S. exchanges in the way Bitcoin or Ether do, custody is non-trivial, and staking it for yield requires operational machinery most allocators do not want to build. Hyperliquid Strategies turns all of that into a Nasdaq ticker. As CEO David Schamis put it bluntly on the Q2 call:

"Our job is to hold the HYPE token."

The company adds three things on top of simply holding. First, staking: it stakes substantially all of its HYPE (target near 100%) with custody at Anchorage Digital Bank, earning protocol rewards that compound the token count without new cash. Second, validator operations: in May 2026 it launched its own Hyperliquid validator in partnership with Unit Labs, which earns commission income and gives the company a governance voice in the network it is betting on. Third, capital-allocation arbitrage: when PURR trades below the value of the HYPE it holds, the company buys back its own stock (accretive to HYPE-per-share); when it trades at a premium, it can issue stock and buy more HYPE (also accretive). Management has framed this around an adjusted-NAV band of roughly 0.9x to 1.1x.

Founding story. This is one of the more unusual corporate origin stories in public markets. The vehicle was assembled by Atlas Merchant Capital, the investment firm of Bob Diamond (former CEO of Barclays) and David Schamis, together with crypto firm Paradigm and other investors, through an entity called Rorschach I LLC. Rather than IPO from scratch, they reverse-merged into Sonnet BioTherapeutics, a struggling Nasdaq-listed clinical-stage oncology biotech, in an $888 million deal announced July 14, 2025 and closed December 2, 2025. The combined company was renamed Hyperliquid Strategies Inc., began trading as PURR on December 3, 2025, and inherited roughly 12.6 million HYPE tokens plus about $305 million in cash at closing. Sonnet's legacy biotech became a wholly owned subsidiary that is being wound down and sold (to Guidant BioTherapeutics), with a one-time $35.6 million in-process-R&D write-off taken in the process. The ticker "PURR" is itself an inside joke: PURR is a memecoin on the Hyperliquid network, and the cat-themed branding signals the company's native-crypto identity.

A concrete walk-through. Suppose a U.S. pension fund wants HYPE exposure but cannot hold the token directly. It buys PURR shares on Nasdaq. The company takes the cash it raises (from share issuance or from its balance sheet), buys HYPE on-chain, moves it into Anchorage custody, and stakes it. The staked HYPE earns rewards roughly continuously, increasing the token pile. The company runs a validator that earns additional commission. Each quarter it marks the HYPE to market - which is why reported "net income" swings violently ($152.5 million profit in one quarter, a $318 million loss in the prior six months, driven almost entirely by HYPE's price). It publishes a live dashboard showing fair value, cash, adjusted NAV, and the trading multiple, and it reports treasury activity weekly. The fund's PURR shares rise and fall with HYPE, plus or minus the premium/discount the market assigns to the wrapper.

Section 2: Business segments

Hyperliquid Strategies is, by design, a single-business company: a HYPE treasury. It has no operating segments in the traditional sense. There is, however, a meaningful structural distinction worth a short sub-section because it explains the financials and the strategy.

The HYPE treasury (the entire business). All economic value is the HYPE token pile plus a cash buffer. The "operations" are accumulation, staking, validating, and capital allocation. There is no product to manufacture, no customers to sell to, and no recurring service revenue beyond staking and validator income. This is closer to a closed-end fund or a commodity-holding vehicle than to an operating company.

The legacy biotech (a runoff, not a segment). The Sonnet BioTherapeutics oncology subsidiary survives only as a disposal. Management has sold the majority of its assets to Guidant BioTherapeutics and written off the acquired IPR&D. It is not a strategic line of business; it is a cost the company is removing. Treat it as a wind-down item, not a segment.

Because there is one real business, the segment-comparison table is not applicable. The relevant breakdowns are balance-sheet composition (HYPE vs cash) and income composition (mark-to-market vs staking vs interest), both of which appear in the charts.

Section 3: Products and business detail

The "product" Hyperliquid Strategies sells is a security - PURR common stock - whose value is engineered to track and compound HYPE per share. Understanding the product therefore requires understanding both the wrapper mechanics and the underlying asset.

The wrapper mechanics (what the company actually does day to day):

• Accumulation. The company deploys cash into HYPE when its capital-allocation framework favors buying the token over buying back stock. Since closing on December 2, 2025, it deployed over $216 million to acquire roughly 7.3 million HYPE at an average price near $29.53, taking holdings from ~12.6 million at close to ~18.8 million at March 31, 2026 and over 20 million by late April 2026 (Q3 FY2026 release, May 7, 2026).
• Staking. Substantially all HYPE is staked, custodied at Anchorage Digital Bank, generating protocol rewards ($2.6 million staking revenue in Q3 FY2026). The stated objective is to stake 100% of holdings.
• Validating. The "Hyperliquid Strategies x Unit" validator, built with Unit Labs, went live around May 11, 2026. It earns validator commission and gives the company governance standing in the network. Schamis described it as both a yield enhancer and a way to "contribute directly to Hyperliquid's decentralization, resilience, and governance."
• Capital allocation. A $30 million stock-repurchase program was authorized December 8, 2025 (up to 12 months); through March 31, 2026 the company repurchased 3,067,097 shares for about $10.6 million at roughly $3.42 per share. It also filed a $1 billion shelf registration (S-1, October 2025; up to ~160 million shares; Chardan Capital Markets advising) to fund further HYPE accumulation, and has issued some stock via the ATM (about $38.4 million at an average $6.31). The governing logic is an adjusted-NAV band of roughly 0.9x-1.1x: buy back stock at a discount, issue and buy HYPE at a premium.
• Transparency tooling. The company runs a live dashboard at hypestrat.xyz showing fair value, cash, adjusted NAV, and trading multiples, refreshed in real time with weekly treasury reporting. It relaunched the site June 16, 2026 with expanded analytics.

The underlying asset (HYPE and Hyperliquid): HYPE is the native token of Hyperliquid, a purpose-built Layer-1 blockchain that runs the dominant on-chain perpetual-futures exchange. Hyperliquid commands roughly 70-80% of decentralized perpetual-derivatives volume, processes very large daily volumes, and generates on the order of $800 million-plus in annual protocol fees. Critically for a treasury holder, Hyperliquid routes the large majority of protocol fees (management cited "approximately 99%") into buying back and burning HYPE, making the token structurally deflationary as long as the exchange generates fees. Hyperliquid raised no venture capital and distributed 31% of supply to users via a late-2024 airdrop. Network features management highlighted include Builder Codes (third-party liquidity access), HIP-3 (permissionless perp front-ends), HLP (cross-collateral position sharing), and HIP-4 (options and prediction markets).

Geography. The company is U.S.-domiciled (New York), Nasdaq-listed, with custody at Anchorage (a U.S. chartered digital-asset bank). Its "market" is global investor demand for HYPE exposure routed through a U.S.-regulated equity wrapper. There is no physical manufacturing or export footprint.

Section 4: Customers

Hyperliquid Strategies has no customers in the operating sense. Its "customers" are its shareholders - the buyers of PURR - and understanding who they are and why they buy is the right way to read demand for the stock.

Who buys PURR. Three overlapping groups. First, U.S. institutions and funds that want HYPE exposure but face mandate, custody, or regulatory constraints on holding the token directly; for them a Nasdaq equity is the only compliant route. Second, crypto-native investors who could buy HYPE themselves but prefer the staking yield, validator income, and potential NAV-accretive buybacks the corporate wrapper provides without operational overhead. Third, retail traders drawn to a liquid, optionable equity (the company launched listed options on PURR) that behaves like a leveraged proxy on HYPE sentiment.

Why they choose it over buying HYPE directly. The pitch, in management's words, is "compounding shareholder returns that individual holders may not be able to replicate" - staking near 100% of the pile, validator commissions, and disciplined capital allocation around NAV. The wrapper also confers access (U.S. exchange listing), custody assurance (Anchorage, a regulated bank), and the credibility of a board stacked with traditional-finance heavyweights.

Switching costs. Essentially zero. A shareholder can sell PURR and buy HYPE directly, rotate into a competing HYPE treasury (Hyperion DeFi, Lion Group, HYLQ), or wait for a spot HYPE ETF. The only stickiness is the premium-to-NAV mechanism: if the market believes management can compound HYPE-per-share, it will pay up, and that belief is the moat. There is no contractual lock-in, no qualification cycle, no installed base.

Concentration. The dominant economic dependency is not customer concentration but single-asset concentration: the entire enterprise is one token. Ownership is also concentrated in the sponsors - Atlas Merchant Capital and Paradigm and affiliated investors hold significant stakes from the merger - which aligns incentives but means the float and governance are sponsor-influenced.

"Contract structure." There is none in the revenue sense. Revenue predictability comes only from staking and validator yields (modest, recurring) layered on top of an inherently volatile mark-to-market asset. There is no subscription, no backlog, no recurring customer contract.

Section 5: Competitive landscape

The competitive question for a HYPE treasury is unusual: it competes less on operations than on which wrapper the market trusts to deliver the most HYPE per share at the lowest premium. Competition comes in three layers.

Layer 1 - other public HYPE treasuries. Several Nasdaq/listed shells have pivoted into HYPE accumulation, mirroring the Strategy-for-Bitcoin playbook. Hyperliquid Strategies is by far the largest by token count, which matters: scale lowers per-share cost of custody, staking, and validator operations, and the sponsor pedigree (Diamond, Schamis, Paradigm) gives it institutional credibility competitors lack.

Layer 2 - direct HYPE ownership and future ETFs. The most important competitor is HYPE itself. Any investor who can self-custody and self-stake captures the same upside without paying a wrapper premium. The looming structural threat is a spot HYPE ETF: Bitwise has filed a Hyperliquid ETF (BHYP) that would allocate a slice of fees to buying and holding HYPE. A low-fee, liquid ETF would compete directly for the access-seeking institutional dollar that is PURR's core customer, and could compress PURR's premium toward (or below) NAV.

Layer 3 - the broader DAT universe. PURR competes for the same "crypto-treasury" capital allocation as Bitcoin treasuries (Strategy and peers), Ether treasuries, and Solana treasuries. When crypto-treasury sentiment cools, premiums across the entire category compress regardless of the specific token.

Market-cap figures are rough peer-size references with the stated as-of dates; they move with crypto prices and are not used here for any valuation of PURR.

Barriers to entry. Low in form, high in substance. Anyone can announce a HYPE treasury (the shell-reverse-merger path is well-trodden), so there is no legal moat. The real barriers are scale, sponsor credibility, and trust: a treasury only sustains a premium if investors believe management will compound HYPE-per-share rather than dilute it. PURR's edge is being the biggest, the best-governed (Anchorage custody, a board of ex-Barclays/ex-NYSE/ex-Fed figures), and the most transparent (live NAV dashboard). That is a reputational moat, not a structural one - and reputational moats erode fast if a buyback turns dilutive or the premium collapses.

This is not a high-margin moat business in disguise. It is a leveraged sentiment vehicle on a single token, competing in a crowded, low-barrier category, where the only durable advantage is being the trusted, scaled incumbent.

Section 6: Industry

The industry here has two layers: the digital-asset-treasury (DAT) vehicle market and the underlying perpetual-DEX market that gives HYPE its value. Both must be understood.

The DAT vehicle market. Demand for crypto-treasury equities is driven by a specific friction: many large pools of capital (pensions, RIAs, mandate-constrained funds, certain international investors) cannot or will not hold tokens directly, but can hold equities. A DAT converts a token into a stock, and historically these vehicles have traded at a premium to the NAV of their holdings during bull phases - the premium being the market's pricing of management's ability to accrete tokens-per-share via cheap capital. The category exploded after Strategy demonstrated the model with Bitcoin; HYPE treasuries are a 2025-2026 vintage of the same idea. The category is intensely cyclical and reflexive: rising token prices justify premiums, premiums enable accretive issuance, issuance buys more tokens, which supports the price - and the cycle runs hard in reverse on the way down.

The underlying perp-DEX market. HYPE's value derives from Hyperliquid's position as the dominant on-chain perpetual-futures venue, with roughly 70-80% of decentralized perp volume and on the order of $800 million-plus in annual protocol fees, the bulk of which fund HYPE buyback-and-burn. The demand driver here is the secular migration of derivatives trading on-chain and the search for a non-custodial alternative to centralized exchanges. This market is growing fast but is competitive (other perp DEXs are emerging) and is itself highly cyclical with crypto trading volumes.

Regulation. This is the single biggest industry-level swing factor. PURR sits at the intersection of securities regulation (it is a Nasdaq issuer) and the evolving U.S. treatment of crypto assets. A friendly regime (clear custody rules, approved spot ETFs) expands the addressable market but also invites ETF competition that could undercut the wrapper premium. A hostile regime (token-as-security enforcement, custody restrictions) could impair the entire model. The company's use of a regulated custodian (Anchorage) and a traditional-finance board is partly a regulatory-credibility play.

Cyclicality. Extreme. The business has no counter-cyclical ballast: in a crypto drawdown, the token falls, the NAV falls, the premium compresses (or flips to a discount), and the capital-raising flywheel jams - exactly when the company would most want cheap capital, it is least available. The Q2 FY2026 results showed this directly: a $318 million six-month loss driven entirely by HYPE's decline from ~$46 at signing to ~$33 at closing and lower thereafter.

Tailwinds: on-chain derivatives growth, HYPE's deflationary buyback-and-burn, institutional appetite for regulated crypto access, and Hyperliquid's expanding feature set (options, prediction markets, permissionless perps). Headwinds: the pending spot HYPE ETF, premium compression across all DATs, perp-DEX competition, and regulatory uncertainty.

Section 7: Growth triggers

Extracted only from the two available Hyperliquid Strategies earnings calls (Q2 FY2026, ~Feb 11, 2026; Q3 FY2026, May 7, 2026) and dated company announcements.

• Validator launch with Unit Labs (live ~May 11, 2026) - new recurring revenue stream from validator commissions plus governance standing. First flagged as a medium-term goal on the Q2 call, then delivered on schedule per the Q3 call (May 7, 2026). Repeated then executed.

  "Expected to create additional revenue opportunities" and deepen ecosystem alignment. (Q3 FY2026 call, May 7, 2026)

• $1 billion shelf registration to fund HYPE accumulation - S-1 filed October 2025, up to ~160 million shares over a multi-year window, Chardan advising. The fuel for continued token accumulation when capital allocation favors buying HYPE. (Company S-1, October 2025; reiterated as accumulation strategy on both calls.)

• Move toward 100% staking of the HYPE pile - management's stated objective is to stake substantially all holdings (already near-full via Anchorage), compounding token count without new cash. (Q2 FY2026 call, ~Feb 11, 2026; reiterated Q3.)

  "Our job is to hold the HYPE token." (Q2 FY2026 call)

• NAV-accretive capital-allocation flywheel (0.9x-1.1x adjusted-NAV band) - buy back PURR below NAV, issue and buy HYPE above NAV; management said the framework "could evolve" as revenue-generating businesses develop within the ecosystem. (Q3 FY2026 call, May 7, 2026.)

  Management described its HYPE-buying-plus-stock-buyback activity as demonstrating "how digital asset treasury companies are supposed to work." (Q3 FY2026 call)

• Completion of legacy biotech disposition (sale to Guidant BioTherapeutics) - removes non-core costs and the IPR&D overhang, leaving a pure-play HYPE treasury. (Q3 FY2026 call, May 7, 2026.)

• Expanding transparency tooling / live NAV dashboard (launched Q2 call; relaunched June 16, 2026) - aimed at widening the institutional and analyst audience and supporting the premium. (Q2 FY2026 call; June 16, 2026 website relaunch.)

• Ecosystem feature expansion underpinning HYPE demand - management highlighted Builder Codes, HIP-3 (permissionless perp front-ends), HLP, and HIP-4 (options/prediction markets) as fee-and-burn drivers for the token it holds. (Q2 FY2026 call, ~Feb 11, 2026.)

Section 8: Key risks

• Single-asset concentration (the defining risk). The entire company is one token. There is no diversification, no operating cash flow to cushion a token crash, and no second business. A sustained HYPE decline takes the whole NAV with it. This is not theoretical: the Q2 FY2026 six-month loss of $318 million was driven almost entirely by HYPE falling from ~$46 at signing to the low-$30s. Calibration: high-probability, high-magnitude volatility is the base condition, not a tail risk.

• Premium-to-NAV collapse. The DAT model only works while the stock trades at or above the value of its holdings, which lets the company issue stock accretively. If sentiment sours and PURR trades at a discount, the issuance flywheel jams, buybacks become the only accretive lever, and the wrapper's reason to exist (compounding HYPE-per-share via cheap capital) disappears. The company's own 0.9x-1.1x framework is an admission that the premium is fragile.

• Spot HYPE ETF competition. A Bitwise (BHYP) or similar low-fee, liquid spot ETF would offer the same HYPE access PURR sells, but cheaper and without a corporate wrapper premium. This could structurally compress PURR toward NAV by removing its access advantage - the closest thing to an existential competitive threat. Management has not been able to point to a durable defense beyond scale and staking/validator yield.

• Regulatory reclassification or custody disruption. PURR depends on HYPE being treatable as a property-like asset and on Anchorage custody remaining viable. A securities-law reclassification of HYPE, or custody/staking restrictions, could impair the model. The company's regulated-custodian and TradFi-board choices are mitigants, not guarantees.

• Reflexive capital-raising fragility. The $1 billion shelf is only useful when markets are open and the stock is strong. In a drawdown - exactly when more HYPE would be cheap - the company would be raising into weakness or unable to raise at all. The model is pro-cyclical by construction.

• Hyperliquid protocol/ecosystem risk. HYPE's value rests on Hyperliquid retaining its ~70-80% perp-DEX dominance and its fee-funded buyback-and-burn. Competitive erosion, a smart-contract exploit, a validator-set failure, or a collapse in trading volumes would hit the token directly. PURR has no hedge against the protocol it is wholly exposed to.

• Key-person and sponsor-overhang risk. The investment thesis leans heavily on Atlas Merchant Capital and Paradigm. Sponsor selling, a change in their commitment, or departure of Schamis/Diamond would damage the credibility premium that distinguishes PURR from sub-scale rivals.

• Tax drag on a non-cash-generating asset. Management has flagged a deferred-tax liability calculated at full HYPE liquidation value (around $18 million impact noted in Q2), a reminder that unrealized gains carry an embedded tax claim even though the company intends never to sell.

Section 9: Walk the talk

Concall dates used: Q2 FY2026 (quarter ended Dec 31, 2025; call ~Feb 11, 2026) and Q3 FY2026 (quarter ended Mar 31, 2026; call May 7, 2026).

I must state the limitation plainly: only two earnings calls exist for Hyperliquid Strategies, because the company has only operated as a HYPE treasury since December 2, 2025. The prompt's six-call requirement cannot be met for this entity, and the pre-merger calls under the same CIK belong to Sonnet BioTherapeutics' oncology business - a different company with no bearing on management credibility here. I assessed the two real calls in full and searched explicitly for any Q4 FY2026 (June 30) call, which has not yet occurred as of June 17, 2026. With only two data points, this is a credibility snapshot, not a multi-year track record.

On the Q2 call (~Feb 11, 2026), management set out a clear, falsifiable agenda: hold and accumulate HYPE; stake substantially all of it at Anchorage; pursue NAV-per-share accretion with disciplined, non-venture-style risk; evaluate becoming a validator as a "medium-term goal"; and launch a transparency dashboard (promised live by end of that very call). They disclosed having deployed ~$140 million since closing - ~$130 million into ~5 million HYPE at sub-$26, and ~$10 million repurchasing 3-plus million shares at $3.42 - with ~17.5 million HYPE held and ~$125 million dry powder.

"Our job is to hold the HYPE token." (Q2 FY2026 call)

By the Q3 call (May 7, 2026), the scorecard is unusually clean for a three-month gap. The validator that was a "medium-term goal" in February was announced and slated to go live around May 11 - delivered faster than guided. The accumulation continued exactly as described: total deployment rose past $216-225 million, holdings climbed to ~18.8 million HYPE at quarter-end and over 20 million by April 29, and the buyback figures reconcile precisely (3,067,097 shares for ~$10.6 million at $3.42, matching the Q2 disclosure and the $30 million authorization from December 8, 2025). The transparency dashboard promised in February exists and was later expanded (June 16, 2026 relaunch). The biotech disposition that was "in progress" was substantially completed, with the $35.6 million IPR&D write-off taken. And management formalized the capital-allocation rule it had described loosely in February into an explicit 0.9x-1.1x adjusted-NAV band, while honestly noting it "could evolve."

Management described its HYPE-and-buyback activity as demonstrating "how digital asset treasury companies are supposed to work." (Q3 FY2026 call, May 7, 2026)

The honest read: across the only two calls available, management did what they said, on or ahead of schedule, and their disclosures reconcile to the penny. That is a positive early signal of execution credibility and unusually high transparency. The large caveats are (a) two calls is a very thin record - there has been no down-cycle test of whether they stay disciplined when the premium collapses and the flywheel jams; and (b) the easy wins (deploy cash, stake, launch a dashboard) are operationally straightforward. The real credibility test - defending HYPE-per-share when forced to choose between dilutive raises and standing still in a drawdown - has not yet arrived. Verdict so far: early signs of a management that does what it says, but on too short a record to call durable.

Section 10: Shareholder friendliness index

Dividends. Hyperliquid Strategies pays no dividend and has never declared one, and none should be expected. As a digital-asset treasury, every available dollar is directed into HYPE accumulation or stock buybacks rather than cash distributions; paying a dividend would defeat the compounding-HYPE-per-share thesis. There is no three-year DPS history to assess because the company has existed in this form only since December 2, 2025 (and the predecessor, Sonnet BioTherapeutics, was a cash-burning clinical-stage biotech that paid no dividend either). DPS: nil in FY2026, nil in any prior year.

Buybacks and dilution. Two windows, stated separately. Older programme (older than ~90 days): the Board authorized a $30 million stock-repurchase program on December 8, 2025, running up to 12 months; through March 31, 2026 the company had repurchased 3,067,097 shares for approximately $10.6 million at about $3.42 per share (company release / 10-Q, May 7, 2026), bought back when PURR traded below HYPE NAV - genuinely accretive to HYPE-per-share. Recent window (last ~90 days, per the MoatMap database block): one buyback filing dated 2026-03-31 with about US$1,138,000 of consideration, which is the latest monthly tranche of that same $30 million program rather than a new authorization. Working against the buyback, the company has also been a net issuer: it issued roughly $38.4 million of stock at an average $6.31 (above NAV, also accretive) and filed a $1 billion shelf to fund further HYPE purchases. So the share count is structurally set to grow, not shrink - by design, because issuing above NAV to buy HYPE increases HYPE-per-share even as the share count rises. The buyback is a tactical tool used only when the stock trades at a discount, not a capital-return commitment. (Sources: 8-K/press release Dec 8, 2025; 10-Q and Q3 release May 7, 2026; S-1 Oct 2025; MoatMap database block, current 2026-06-17.)

Verdict: Neutral, leaning shareholder-aligned-but-not-cash-returning. The company returns no cash and will dilute via its shelf, but every capital action (buy below NAV, issue above NAV) is explicitly engineered to grow HYPE-per-share rather than to enrich management or chase scale for its own sake - the single most important reason it earns "neutral" rather than "hoards capital."

Section 11: Insider activities

Source note. The US venue is open (SEC Form 4 via EDGAR), so per the prompt the injected MoatMap database block is the spine (current as of 2026-06-17), cross-checked against primary sources for the most recent ~2 weeks. Direct fetches to EDGAR's browse interface and to OpenInsider were blocked/refused within this session's budget, so the MoatMap rows below are the authoritative record; I found no news of any open-market insider purchase or sale in the trailing two weeks to add.

Recent transactions (last 12 months). All four recorded insider transactions are the same event type on the same date - director equity, not open-market trading:

(All rows: Form 4, 2026-04-01, per MoatMap/EDGAR.)

Buys - read the signal. There are no open-market purchases by any insider in the window. The four April 1, 2026 transactions are board equity grants (recorded at $0 price, classified "Other"), the routine annual-retainer mechanism for independent directors, not conviction buys. They carry no directional signal - a director receiving stock as compensation is not the same as a director spending cash to buy it.

Sells - work out the why. There are no open-market sales by insiders in the window either. Nothing to explain.

Net assessment. Insider activity over the last 12 months is neutral and uninformative: zero open-market buys, zero open-market sells, and four routine director equity grants on a single date. The most important caveat is structural rather than from the trade tape - the true insider exposure here is the sponsors' merger stakes (Atlas Merchant Capital, Paradigm and affiliated investors), which dwarf any director grant and whose future disposition (via Schedule 13D/G or Form 4 if they cross thresholds) is the holding worth watching. As of this report, no sponsor selling has surfaced. Read: neutral - the absence of open-market buying means there is no bullish conviction signal to point to, but the absence of selling means no red flag either. For a six-month-old treasury vehicle, that is unremarkable.

Section 12: Scenarios

Bull case. HYPE's structural deflation does the heavy lifting. Hyperliquid keeps its 70-80% grip on on-chain perpetuals, trading volumes keep climbing as derivatives migrate on-chain, and the ~99%-of-fees buyback-and-burn steadily shrinks supply against rising demand - the token compounds. Hyperliquid Strategies, as the largest and best-governed wrapper, sustains a premium to NAV, which lets it issue stock above NAV and buy ever more HYPE, mechanically lifting HYPE-per-share. Staking near 100% and the Unit Labs validator throw off a growing token-denominated yield that compounds the pile without new cash. The TradFi board (Diamond, Schamis, Rosengren, Leibowitz, King) wins institutional mandates that cannot touch tokens directly, and the $1 billion shelf gets deployed into a rising asset. Even a spot HYPE ETF, when it arrives, validates the asset class and lifts HYPE broadly rather than killing PURR, because PURR's staking-plus-validator yield and accretive capital allocation still beat passive holding. Two or three years out, the company is a multiple of its current token count, trades at a healthy premium, and is the default public way to own HYPE.

Base case. Management does roughly what it has said: keeps accumulating HYPE when capital is cheap, stakes the pile, runs the validator, and uses the $30 million-class buyback opportunistically when the stock dips below NAV. HYPE rises and falls with crypto cycles, dragging reported earnings through wild mark-to-market swings (a $150 million profit one quarter, a loss the next) that mean little for the underlying thesis. The premium to NAV oscillates - fat in risk-on phases, thin or briefly negative in drawdowns - but does not permanently collapse, so the issuance flywheel keeps working in fits and starts. The legacy biotech is fully gone, costs are lean, and the company remains the scale leader among HYPE treasuries. It neither dazzles nor disappoints: a faithful, transparent, single-asset compounding vehicle whose fortunes are dominated by HYPE's own path. The arrival of a spot HYPE ETF compresses the premium somewhat, nudging management to lean harder on staking/validator yield to justify the wrapper.

Bear case. The reflexivity that powers the model runs in reverse. A crypto-wide drawdown drags HYPE down hard; the NAV craters and the premium flips to a persistent discount, freezing the accretive-issuance flywheel exactly when cheap HYPE is available - the $1 billion shelf becomes unusable dead weight. A low-fee spot HYPE ETF launches and strips away PURR's access advantage, leaving investors asking why they should pay a corporate wrapper at all; the discount widens. Worse, a shock to Hyperliquid itself - a competitor eroding its perp-DEX dominance, a protocol exploit, a validator-set or custody failure, or a regulatory reclassification of HYPE as a security - hits the one asset the company owns with no hedge and no diversification. Sponsor selling (Atlas, Paradigm) into a falling market crushes the credibility premium. With no operating cash flow, no dividend, and a single volatile asset marked to market, PURR becomes a discounted, illiquid claim on a depressed token, and the wrapper's reason to exist evaporates.

Note on Section 13 (Further Reading): I searched SemiAnalysis, Stratechery, and MBI Deep Dives for in-depth coverage of Hyperliquid Strategies / PURR / HYPE. None of the three has published a qualifying article centrally about this company (SemiAnalysis is semiconductor/datacenter-focused; Stratechery and MBI Deep Dives did not return company-specific coverage). Per the empty-case rule, the section is omitted rather than padded.

Sources

• Hyperliquid Strategies Q3 FY2026 results (PR Newswire, 2026-05-07)
• Q3 FY2026 10-Q (SEC EDGAR)
• Q3 FY2026 earnings call highlights (The Stock Observer, 2026-05-08)
• Q2 FY2026 earnings call (Yahoo Finance)
• Sonnet + Rorschach / Atlas + Paradigm $888m merger (The Block)
• Closing of business combination (Sonnet/PURR IR)
• $1 billion shelf registration to raise for HYPE (The Block)
• $30 million stock repurchase program (Nasdaq, 2025-12-08)
• Company website / IR (hypestrat.xyz)
• Hyperliquid perp-DEX dominance & HYPE fees (Yellow.com research)
• HYPE treasury competitors: Hyperion DeFi, Lion Group, HYLQ (The Block treasuries; KuCoin)
• Atlas Merchant Capital / Bob Diamond & David Schamis (CNBC interview)

A short housekeeping flag: the deliverable was requested as a .md file, but I can only emit text in this session - I cannot write to your filesystem outside the tools available here. If you want this saved into the repo (e.g. reports/PURR_deep_dive.md), say so and I will format it for that path, or you can copy the block above. Want me to also save a one-line memory noting the PURR report structure/constraints (two-concall limit) for future DAT deep dives?